4D Molecular Therapeutics Inc at Goldman Sachs Global Healthcare Conference Transcript
Good morning, everyone, and thank you for joining us for day 3 of the Goldman Sachs Healthcare Conference. We're really pleased to have 4D Molecular Therapeutics. And with us, we have David Kirn, Co-Founder and President and CEO of the company.
Questions & Answers
With that, David, to start here, the company has demonstrated early proof of concept for multiple assets, including a drug for Fabry disease and one in an eye disease XLRP. Can you share your outlook for the near term and highlight your key events investors should be focused on next?
Well, first of all, thanks for having us, Salveen.
And just by way of background for the AAV of genetic medicines company, we have 5 products in the clinic across 3 therapeutic areas, all of which leverage vectors that we
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |